TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1688914

Group type: EXPERIMENTAL
Intervention: Mild hypervolaemic haemodilution with hydroxyethyl starch (HES) combined with exercise (3 times weekly) for 6 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ringer lactate combined with exercise (3 times weekly) for 6 weeks
Number of subjects: 75

Group type: COMPARATOR
Intervention: Exercise alone (3 times weekly)
Number of subjects: 75
Study: 6586147

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg once weekly)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Penicillamine (250 mg daily)
Number of subjects: 28
Study: 30893022

Group type: EXPERIMENTAL
Intervention: Kinesiology taping of the hemiplegic shoulder
Number of subjects: 10
Study: 30149798

Group type: EXPERIMENTAL
Intervention: Detection and prevention program for frailty
Number of subjects: 900

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 900
Study: 27088096

Group type: EXPERIMENTAL
Intervention: ABC continued group (n = 25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: ABC discontinued group (n = 24)
Number of subjects: 49
Study: 24445546

Group type: EXPERIMENTAL
Intervention: Antioxidant supplemented group (SUP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 54
Study: 23783296

Group type: EXPERIMENTAL
Intervention: Formula containing docosahexaenoic acid and arachidonic acid (LC-PUFA)
Number of subjects: 235

Group type: COMPARATOR
Intervention: No LC-PUFAs (control)
Number of subjects: 235
Study: 19958072

Group type: EXPERIMENTAL
Intervention: Modified anastomosis with posterior and anterior fixation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Typical Van Velthoven vesicourethral anastomosis
Number of subjects: 47
Study: 18548178

Group type: EXPERIMENTAL
Intervention: Early intensive physiotherapy rehabilitation on day 1 to 2 after admission until clinical stability
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 76
Study: 15947609

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 28 days
Number of subjects: 377

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily for 28 days
Number of subjects: 377
Study: 12947315

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol-treated islets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 0
Study: 9892125

Group type: EXPERIMENTAL
Intervention: Foot pump (intermittent pneumatic pedal compression device)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (bulky compression dressing, posterior splint, elevation)
Number of subjects: 28
Study: 8902991

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg once daily for 10 days
Number of subjects: 442

Group type: COMPARATOR
Intervention: Unfractionated heparin 5000 IU twice daily for 10 days
Number of subjects: 442
Study: 1831798

Group type: EXPERIMENTAL
Intervention: 100 mg DMPA plus 100 mg TE monthly (Group I)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 200 mg DMPA plus 250 mg TE monthly (Group II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both steroid regimens (Group I and Group II)
Number of subjects: 20
Study: 6753611

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.125 mg, 0.25 mg, or 0.50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Physostigmine (previously associated dose)
Number of subjects: 10
Study: 30932508

Group type: EXPERIMENTAL
Intervention: IPS supported employment
Number of subjects: 541

Group type: COMPARATOR
Intervention: TW (transitional work) assignments
Number of subjects: 541
Study: 28832750

Group type: EXPERIMENTAL
Intervention: Mood disorder treatment algorithms
Number of subjects: 259
Study: 26400993

Group type: EXPERIMENTAL
Intervention: Monovalent RV vaccine (RV1) administered to infants
Number of subjects: 107
Study: 25396674

Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment 1% (plus oral placebo), twice daily for 5 days
Number of subjects: 404

Group type: COMPARATOR
Intervention: Oral linezolid (plus placebo ointment) 2 or 3 times daily for 10 days
Number of subjects: 404
Study: 22974370

Group type: EXPERIMENTAL
Intervention: Nd:YAG 1064-nm laser (n=20, 8 J/cm2, 0.25 W, 10 Hz, 10 sec)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 808-nm diode laser (n=20, 8 J/cm2, 0.25 W, continuous mode, 10 sec)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 660-nm diode laser (n=20, 8 J/cm2, 0.04 W, continuous mode, 60 sec)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo laser control (n=20)
Number of subjects: 80
Study: 20661659

Group type: EXPERIMENTAL
Intervention: BIB (6 months) followed by diet therapy (7 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: BIB followed by another BIB after 1 month
Number of subjects: 100
Study: 17462827

Group type: EXPERIMENTAL
Intervention: Early enteral resuscitation and feeding (ER/EEF) initiated within a median of 10.7h post-burn
Number of subjects: 15

Group type: COMPARATOR
Intervention: Late enteral feeding (LEF) introduced on average 54h post-burn
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ER/EEF
Number of subjects: 15
Study: 15204272

Group type: EXPERIMENTAL
Intervention: Real world assembly instructions
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Abstract assembly instructions
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Task variables identified
Number of subjects: 114
Study: 12366892

Group type: EXPERIMENTAL
Intervention: Stage-matched nutrition counseling by family physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 9641475

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) 7.2 g per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7865703

Group type: EXPERIMENTAL
Intervention: 2.4 g of piracetam
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 4.8 g of piracetam
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 2770269

Group type: EXPERIMENTAL
Intervention: L-arginine and L-ornithine (2 grams and 1 gram respectively)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (600 mg of calcium and 1 gram of Vitamin C)
Number of subjects: 22
Study: 143795

Group type: EXPERIMENTAL
Intervention: Live mumps vaccine from the L-3 strain, 1 dose containing 104HAdU50 of mumps virus
Number of subjects: 113967

Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 113967

Group type: EXPERIMENTAL
Intervention: Urgent vaccination prophylaxis in children's institutions
Number of subjects: 113967

Group type: EXPERIMENTAL
Intervention: Mass prophylaxis by vaccination
Number of subjects: 113967
Study: 30747548

Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 170
Study: 28327932

Group type: EXPERIMENTAL
Intervention: Rolapitant 180 mg oral
Number of subjects: 2595

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2595

Group type: COMPARATOR
Intervention: Rolapitant and Control (both groups)
Number of subjects: 2595
Study: 26123682

Group type: EXPERIMENTAL
Intervention: Higher volume red wine (218 g alcohol/wk)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lower volume red wine (73 g alcohol/wk)
Number of subjects: 24
Study: 24019545

Group type: EXPERIMENTAL
Intervention: Tivozanib
Number of subjects: 517

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 517
Study: 22001171

Group type: EXPERIMENTAL
Intervention: Brand 1 (Caballero Smooth Flavor; 0.89 mg ammonium per gram tobacco)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Brand 2 (Gauloise Brunes; 3.43 mg ammonium per gram tobacco)
Number of subjects: 51
Study: 19500510

Group type: EXPERIMENTAL
Intervention: CRRT without heparin
Number of subjects: 16

Group type: COMPARATOR
Intervention: CRRT with heparin
Number of subjects: 16
Study: 16009365

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.0 g/d
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Colesevelam HCl 3.75 g/d
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 12796731

Group type: EXPERIMENTAL
Intervention: Hydro-Jet-assisted dissection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 80
Study: 11707825

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam and 2 mg hydromorphone p.o. for the contralateral BMBA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for the first BMBA and placebo for the contralateral BMBA
Number of subjects: 25
Study: 8970608

Group type: EXPERIMENTAL
Intervention: Oduli‐momab (anti‐LFA‐1 mAb)
Number of subjects: 101

Group type: COMPARATOR
Intervention: rATG
Number of subjects: 101
Study: 1591067

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (optimal dose 600 mg/m2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (600 mg/m2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin 90 mg/m2 plus intravenous etoposide (800 mg/m2)
Number of subjects: 40
Study: 2412040

Group type: EXPERIMENTAL
Intervention: Ketanserin (Kn)
Number of subjects: 17
Study: 31411096

Group type: EXPERIMENTAL
Intervention: PA delivered VOPD consultation service
Number of subjects: 191
Study: 29385055

Group type: EXPERIMENTAL
Intervention: sweet LED preload (low energy density, 50 kcal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: savoury LED preload (low energy density, 50 kcal)
Number of subjects: 32

Group type: COMPARATOR
Intervention: HED preloads (high energy density, 250 kcal)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LED preloads (low energy density, 50 kcal)
Number of subjects: 32
Study: 28066102

Group type: EXPERIMENTAL
Intervention: Tinidazole 500 mg once daily + placebo for 5 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice daily for 5 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 120
Study: 25399273

Group type: EXPERIMENTAL
Intervention: Vascular Closure Devices (VCD)
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Intravascular VCD
Number of subjects: 4524

Group type: COMPARATOR
Intervention: Manual Compression
Number of subjects: 4524
Study: 23027821

Group type: COMPARATOR
Intervention: α(1) adrenergic agonist (phenylephrine, PE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: α(2) adrenergic agonist (clonidine, CL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Muscle sympathetic nerve activity (MSNA)
Number of subjects: 30
Study: 20651418

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity intervention (LIFE)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Structured exercise intervention (STRU)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 126
Study: 18929012

Group type: EXPERIMENTAL
Intervention: Motivational interviewing‐based telephone counseling (1 in-person session + 5 telephone sessions)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Exerciser subgroup
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control condition (wait-list)
Number of subjects: 130
Study: 12914552

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active standard control
Number of subjects: 0
Study: 10986541

Group type: EXPERIMENTAL
Intervention: Training programme for general practitioners' reception staff
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fixed effect (FE) summary statistic method
Number of subjects: 26

Group type: COMPARATOR
Intervention: Ordinary logistic regression
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Marginal model based on generalized estimating equations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Random effects (RE) summary statistic method
Number of subjects: 26
Study: 9190848

Group type: EXPERIMENTAL
Intervention: dynorphin A(1-13) 0.1 mg/kg, 0.32 mg/kg, 1 mg/kg (15-min i.v. infusion)
Number of subjects: 6

Group type: COMPARATOR
Intervention: dynorphin A(1-13) 1 mg/kg (15-min i.v.) after morphine pretreatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: morphine pretreatment 45 mg/70 kg i.m.
Number of subjects: 6
Study: 8398289

Group type: EXPERIMENTAL
Intervention: doxifluridine (dFUR) 4000 mg/m2 daily for 5 days every 28 days
Number of subjects: 222

Group type: COMPARATOR
Intervention: fluorouracil (FU) 500 mg/m2 daily for 5 days every 28 days
Number of subjects: 222
Study: 3299905

Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg single oral dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) (50 mg daily for two days and 100 mg twice daily for the following six days, total 1.3 g in eight days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 30
Study: 30187287

Group type: EXPERIMENTAL
Intervention: Pharmacy-based protocol and tailored patient instruction materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27905340

Group type: EXPERIMENTAL
Intervention: Brinzolamide (one drop preinjection)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Ranibizumab IVI (control group)
Number of subjects: 352
Study: 24381054

Group type: EXPERIMENTAL
Intervention: Epirubicin followed by CMF (4 cycles each)
Number of subjects: 705

Group type: COMPARATOR
Intervention: CMF (6 cycles) alone
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 705
Study: 22833662

Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) cultivar CDC Fibar
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) cultivar AC Parkhill
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: White pearled barley (WP) cultivar CDC Fibar
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: White pearled barley (WP) cultivar AC Parkhill
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) pasta AC Parkhill
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) pasta Celebrity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: White pearled barley (WP) pasta
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Whole-grain barley (WG) pasta
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pooled data from Expts. 1 and 2
Number of subjects: 30
Study: 20458906

Group type: EXPERIMENTAL
Intervention: TEAS + GA
Number of subjects: 60

Group type: COMPARATOR
Intervention: GA
Number of subjects: 60
Study: 18279685

Group type: COMPARATOR
Intervention: 7-day hormone-free interval (HFI) with placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 84/7-day cycle of 150 mcg LNG/30 mcg EE for 84 days followed by 7 days of 10 mcg EE
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 21/7-day cycle of 150 mcg LNG/30 mcg EE for 21 days followed by 7 days of placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 7-day EE-supplemented interval after 84 days of an extended OC
Number of subjects: 33
Study: 15731988

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) function assessment using the Tei index in fetuses with TVD
Number of subjects: 31
Study: 14688542

Group type: EXPERIMENTAL
Intervention: Rinehart Reeves lens
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mountford BE lens
Number of subjects: 60

Group type: COMPARATOR
Intervention: DreimLens
Number of subjects: 60

Group type: COMPARATOR
Intervention: Contex D Series 4 lens
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All lens types
Number of subjects: 60
Study: 10367614

Group type: EXPERIMENTAL
Intervention: Counterdependency Scale (CDS) administered to patients with chronic pain
Number of subjects: 150
Study: 8897388

Group type: EXPERIMENTAL
Intervention: CHO‐7 (7% carbohydrate‐electrolyte solution)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CHO‐0/21 (placebo for first 90 min then a 21% glucose solution)
Number of subjects: 8

Group type: COMPARATOR
Intervention: CON (artificially sweetened placebo)
Number of subjects: 8
Study: 1825972

Group type: EXPERIMENTAL
Intervention: 300 mg etodolac twice daily (n = 31)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 50 mg indomethacin 3-times daily (n = 33)
Number of subjects: 64
Study: 6638001

Group type: EXPERIMENTAL
Intervention: Screened group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 0
Study: 31888378

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) (n = 302)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo (n = 305)
Number of subjects: 607
Study: 30985534

Group type: EXPERIMENTAL
Intervention: 81 mg aspirin
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study: 28880047

Group type: EXPERIMENTAL
Intervention: Secure messaging application (WhatsApp)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Telephone (standard communication)
Number of subjects: 345
Study: 27023257

Group type: EXPERIMENTAL
Intervention: Intrathecal ropivacaine
Number of subjects: 133
Study: 24872006

Group type: EXPERIMENTAL
Intervention: Virtual monoenergetic reconstructions at 60 keV
Number of subjects: 71

Group type: COMPARATOR
Intervention: M‐0.3 series (linear blending setting emulating 120 kV acquisition)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 80 keV series
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 100 keV series
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 40 keV
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 60 keV
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: M‐0.3 series
Number of subjects: 71
Study: 22936795

Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Number of subjects: 800

Group type: COMPARATOR
Intervention: No dietary intervention (Control)
Number of subjects: 800
Study: 19886982

Group type: EXPERIMENTAL
Intervention: Daily dosing of isoniazid
Number of subjects: 324

Group type: COMPARATOR
Intervention: Three times a week dosing of isoniazid
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Both dosing schedules (daily and three times a week)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Children from overcrowded homes
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Children older than 4 years
Number of subjects: 324
Study: 17357792

Group type: EXPERIMENTAL
Intervention: Resistance exercise (intermittent free weight squatting at 70% of 1‐RM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aerobic exercise (30 min of continuous cycling at 70% of VO(2max))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 10
Study: 15297100

Group type: EXPERIMENTAL
Intervention: Roti
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Bread
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Rice
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (Non-diabetic subjects)
Number of subjects: 65
Study: 11328332

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 1522
Study: 9221683

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (8 to 12 sessions at absolute atmosphere of 1.3‐1.6 for 40 min)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Aspirin (125 mg daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hyperbaric oxygenation
Number of subjects: 65
Study: 8424516

Group type: EXPERIMENTAL
Intervention: Intravenous glucose at 10 g/h during the operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no glucose)
Number of subjects: 20
Study: 3475193

Group type: COMPARATOR
Intervention: Manually operated ventilation bag (group C)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tidal volume meter at the exhalation valve of the ventilation bag (group V)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Portable ventilator set to the minute volume (group O)
Number of subjects: 30
Study: 29970638

Group type: EXPERIMENTAL
Intervention: Essential oil of Ocimum sanctum
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple antibiotic paste (TAP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 27480449

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 24916176

Group type: EXPERIMENTAL
Intervention: Interactive educational intervention (IE)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Didactic educational intervention (DE)
Number of subjects: 28
Study: 22926608

Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 20533106

Group type: EXPERIMENTAL
Intervention: 7-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 14-day therapy with lansoprazole (30 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicillin (1000 mg b.i.d.)
Number of subjects: 91
Study: 18221441

Group type: EXPERIMENTAL
Intervention: Applied Relaxation (AR) for 12 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 49
Study: 16319343

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 12684649

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (6 mg or 100 microg/kg, single SC injection on day 2 of chemotherapy cycle)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Filgrastim (5 microg/kg/day, daily SC injections until ANC > or =10 x 10(9)/l or for up to 14 days)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim and Filgrastim
Number of subjects: 448
Study: 14740590

Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TIVA by propofol (Group P)
Number of subjects: 40